NCT00775736View on ClinicalTrials.gov

Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin

CompletedOBSERVATIONAL
Enrollment

611

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart 30

Start dose and frequency and safety data collection at the discretion of the physician following clinical practice

DRUG

biphasic insulin aspart 50

Start dose and frequency and safety data collection at the discretion of the physician following clinical practice

DRUG

biphasic insulin aspart 70

Start dose and frequency and safety data collection at the discretion of the physician following clinical practice

Trial Locations (2)

1070

Novo Nordisk Investigational Site, Brussels

Unknown

Novo Nordisk Investigational Site, Luxembourg

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY